Plasma is the lifeblood of Grifols, serving because the uncooked materials for the organic medicines that generate many of the firm’s income. However the Barcelona-based agency has eyed growth past plasma-derived merchandise and its acquisition of GigaGen provides the corporate the chance so as to add antibody medicine to its pipeline.
Grifols stated it paid $80 million to amass the remaining shares of GigaGen that it didn’t personal, representing about 56% of the South San Francisco-based startup. Grifols had acquired a 44% stake in 2017 for $35 million. That deal additionally started a analysis collaboration creating engineered antibody therapies derived from human B cells.
GigaGen develops its therapies by beginning with blood samples from donors. The corporate’s know-how, known as Surge, makes use of these samples to construct a library of antibodies, from which particular antibodies are chosen for his or her potential to deal with a pathogen. These therapies are polyclonal, which means they’re comprised of a number of antibodies. The corporate provides that its antibodies are engineered to be stronger than plasma-derived therapies.
The biotech initially targeted on creating therapies for immune deficiency, infectious ailments, and cancers that resist remedy by a sort of immunotherapy known as checkpoint inhibitors. Because the pandemic unfold final yr, GigaGen turned its consideration to creating antibody therapies for Covid-19. Lead GigaGen drug candidate GIGA-2050 is comprised of greater than 12,000 antibodies from the blood of 16 “distinctive responders” to Covid an infection.
Grifols and GigaGen say GIGA-2050 has robust binding exercise in opposition to pure variants of the novel coronavirus, together with the variants which have just lately emerged in a number of completely different areas around the globe. Grifols is buying its accomplice simply because the Covid drug candidate is about to start medical testing. Grifols stated the FDA has cleared the drug to start a Section 1 examine to evaluate the protection and tolerability of a single dose. The medical trial will enroll as much as 18 sufferers hospitalized with confirmed circumstances of Covid an infection.
The upcoming medical trial might have implications past Covid-19. Grifols stated the examine will even exhibit the protection of GigaGen’s proprietary platform know-how for manufacturing its antibody medicine particular to infectious ailments. These medicine might be rapidly developed for treating rising pathogens.
Grifols makes its therapies by isolating and purifying proteins that come from plasma. Its portfolio doesn’t at present embody merchandise comprised of engineered proteins, although its pipeline consists of engineered variations of alpha-1 proteinase inhibitor (A1P1) and plasmin. A1P1 treats a uncommon type of emphysema whereas plasmin addresses blood-clotting issues.
“The progress that GigaGen is making to spice up the following era of antibody medicine, together with the world’s first recombinant immunoglobulin, will improve Grifols’s innovation efforts, aiming illness administration past plasma-derived therapies,” José Terencio, the corporate’s vice chairman of innovation, stated in a ready assertion.
Grifols’s plasma-derived therapies come from the corporate’s bioscience division, which tallied greater than €3.2 billion (about $3.8 billion) in income in 2020 by means of the third quarter, a 9.9% improve in comparison with the identical interval within the prior yr. Within the 9 months ending Sept. 30, 2020, Grifols reported €4 billion (about $4.8 billion) in web income.
Development of the bioscience division is supported by the addition of plasma donation facilities. In its 2019 annual report, Grifols set a aim of getting 370 plasma assortment facilities by 2024. A deal introduced earlier this month strikes the corporate nearer to its goal. Grifols paid $370 million to amass 25 plasma donation facilities from BPL Plasma. In accordance with Grifols, these facilities collected about 1 million liters of plasma within the final yr.
The addition of the BPL facilities brings Grifols’s complete variety of plasma facilities to 344, of which 298 are primarily based within the U.S. The growth plan is predicted to Grifols’s plasma provide by 30% in 2021, in accordance with the corporate’s report of third quarter monetary outcomes. The corporate additionally stated it plans to open between 15 and 20 new plasma facilities this yr. These services embody plasma facilities in Egypt, stemming from an alliance signed with the Egyptian authorities final November.
Picture: Josep Lago/AFP, by way of Getty Pictures